Kinnate Biopharma, Inc. (KNTE)
| Market Cap | 187.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.76M |
| Shares Out | 6.77M |
| EPS (ttm) | -5.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $27.64 |
| Previous Close | $29.64 |
| Change ($) | -2.01 |
| Change (%) | -6.76% |
| Day's Open | 29.31 |
| Day's Range | 27.17 - 29.34 |
| Day's Volume | 46,577 |
| 52-Week Range | 24.14 - 48.75 |
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...
SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...
Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in ...
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., ...
KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.
Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on Nasdaq und...
Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.
Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 mill...
SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of that range.
The firm is developing treatments for various cancers using a kinase inhibitory approach.
Kinnate Biopharma, an oncology biotech developing small molecule kinase inhibitors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Kinnate Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
About KNTE
Kinnate Biopharma Inc. is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which we collectively refer to as our Kinnate Discovery Engine, to develop our targeted therapies. We focus our discovery and d... [Read more...]
| Industry Biotechnology | IPO Date Dec 3, 2020 |
| CEO Nima Farzan | Employees 31 |
| Stock Exchange NASDAQ | Ticker Symbol KNTE |
Analyst Forecasts
According to 4 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 50.00, which is an increase of 80.93% from the latest price.